Humana faces backlash for hiking breast cancer drug copays

(By Morgan Haefner for Becker’s Hospital Review)

Humana recently reclassified Herceptin — an intravenous drug used to treat metastatic breast cancer — as a nonpreferred drug in some Florida markets, CBS12 reports. Continue reading article here…

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.

 

Leave a Reply